2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow JS207: new trials by email Literature Review of JS207 trials Research Report on JS207
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC JS207, Pemetrexed injection, Platinum - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 69 | 2025-06-19 | 2026-08-04 |
| JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma, surgery, Radiochemotherapy - NSCLC | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-05-20 | 2026-07-27 |
Carcinoma, Non-Small-Cell Lung (1)
Shanghai Junshi Bioscience Co., Ltd. (2)
China (2)